AR088799A1 - CARBOXAMIDE AND UREA DERIVATIVES BASED ON SUBSTITUTED PIRAZOLILS CONTAINING A REPLACED FENILE PORTION WITH A GROUP THAT CONTAINS SO₂ AS VANILLOID RECEIVER LIGANDS - Google Patents
CARBOXAMIDE AND UREA DERIVATIVES BASED ON SUBSTITUTED PIRAZOLILS CONTAINING A REPLACED FENILE PORTION WITH A GROUP THAT CONTAINS SO₂ AS VANILLOID RECEIVER LIGANDSInfo
- Publication number
- AR088799A1 AR088799A1 ARP120104205A ARP120104205A AR088799A1 AR 088799 A1 AR088799 A1 AR 088799A1 AR P120104205 A ARP120104205 A AR P120104205A AR P120104205 A ARP120104205 A AR P120104205A AR 088799 A1 AR088799 A1 AR 088799A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- substituted
- pirazolils
- fenile
- Prior art date
Links
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 9
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 3
- 101100495923 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr2 gene Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A61P23/02—Local anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
Abstract
Compuestos para usarse en el tratamiento y/o profilaxis del dolor y enfermedades y/o trastornos adicionales. Reivindicación 1: Un compuesto de fórmula general (1), en la cual R¹⁰¹, R¹⁰² y R¹⁰³ son, independientemente uno del otro, seleccionados del grupo que consiste de H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, CH₂-OH, CH₂CH₂-OH, CH₂-OCH₃, CH₂CH₂-OCH₃, OCFH₂, OCF₂H, OCF₃, OH, NH₂, un alquilo C₁₋₄, un alquilo O-C₁₋₄, un alquilo NH-C₁₋₄, y un N(alquil C₁₋₄)₂, donde el alquilo C₁₋₄ está en cada caso no sustituido; R² representa CF₃, un alquilo C₁₋₄ no sustituido o un cicloalquilo C₃₋₆ no sustituido; R⁷ y R⁹ son, independientemente uno del otro, seleccionados del grupo que consiste de H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, OH, OCF₃, un alquilo C₁₋₄, y un O-alquilo C₁₋₄, donde el alquilo C₁₋₄ está en cada caso no sustituido; A denota N, CH o C(CH₃); t denota 0, 1 ó 2; R¹⁰⁸ representa alquilo C₁₋₄, el cual no está sustituido o mono-, di- o trisustituido con 1, 2 ó 3 sustituyentes seleccionados del grupo que consiste de F, Cl, Br, OH, =O y OCH₃, opcionalmente en forma de un estereoisómero individual o una mezcla de estereoisómeros, en forma del compuesto libre y/o una sal fisiológicamente aceptable de los mismos.Compounds for use in the treatment and / or prophylaxis of pain and diseases and / or additional disorders. Claim 1: A compound of the general formula (1), in which R¹⁰¹, R¹⁰² and R¹⁰³ are, independently of one another, selected from the group consisting of H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, CH₂ -OH, CH₂CH₂-OH, CH₂-OCH₃, CH₂CH₂-OCH₃, OCFH₂, OCF₂H, OCF₃, OH, NH₂, a C₁₋₄ alkyl, an O-C₁₋₄ alkyl, an NH-C₁₋₄ alkyl, and an N (C₁₋₄ alkyl) ₂, where the C₁₋₄ alkyl is in each case unsubstituted; R² represents CF₃, an unsubstituted C₁₋₄ alkyl or an unsubstituted C₃₋₆ cycloalkyl; R⁷ and R⁹ are, independently of each other, selected from the group consisting of H, F, Cl, Br, CFH₂, CF₂H, CF₃, CN, OH, OCF₃, a C₁₋₄ alkyl, and a C₁₋₄ O-alkyl , where the C₁₋₄ alkyl is in each case unsubstituted; A denotes N, CH or C (CH₃); t denotes 0, 1 or 2; R¹⁰⁸ represents C₁₋₄ alkyl, which is not substituted or mono-, di- or trisubstituted with 1, 2 or 3 substituents selected from the group consisting of F, Cl, Br, OH, = O and OCH₃, optionally in the form of an individual stereoisomer or a mixture of stereoisomers, in the form of the free compound and / or a physiologically acceptable salt thereof.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11008927 | 2011-11-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR088799A1 true AR088799A1 (en) | 2014-07-10 |
Family
ID=47143914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120104205A AR088799A1 (en) | 2011-11-09 | 2012-11-08 | CARBOXAMIDE AND UREA DERIVATIVES BASED ON SUBSTITUTED PIRAZOLILS CONTAINING A REPLACED FENILE PORTION WITH A GROUP THAT CONTAINS SO₂ AS VANILLOID RECEIVER LIGANDS |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2776401A1 (en) |
| JP (1) | JP2014532744A (en) |
| KR (1) | KR20140091041A (en) |
| CN (1) | CN104066720A (en) |
| AR (1) | AR088799A1 (en) |
| AU (1) | AU2012334068A1 (en) |
| BR (1) | BR112014011108A2 (en) |
| CA (1) | CA2854424A1 (en) |
| HK (1) | HK1202117A1 (en) |
| IN (1) | IN2014KN00865A (en) |
| MX (1) | MX2014005233A (en) |
| TW (1) | TW201326135A (en) |
| WO (1) | WO2013068464A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201607267SA (en) | 2014-03-07 | 2016-09-29 | Biocryst Pharm Inc | Human plasma kallikrein inhibitors |
| CN107108593B (en) * | 2014-11-24 | 2020-03-24 | 美迪福伦Dbt有限公司 | Substituted oxazole and thiazole-based carboxamide and urea derivatives as vanilloid receptor ligands II |
| CN114920697A (en) * | 2022-05-16 | 2022-08-19 | 河南应用技术职业学院 | Heterocyclic group substituted indan propionamide compound and application thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2011011797A (en) | 2009-05-07 | 2011-11-29 | Gruenenthal Gmbh | Substituted phenyllureas and phenylamides as vanilloid receptor ligands. |
| PL2427436T3 (en) | 2009-05-07 | 2013-06-28 | Gruenenthal Gmbh | Substituted aromatic carboxamide and urea derivatives as vanilloid receptor ligands |
-
2012
- 2012-11-08 BR BR112014011108A patent/BR112014011108A2/en not_active IP Right Cessation
- 2012-11-08 AU AU2012334068A patent/AU2012334068A1/en not_active Abandoned
- 2012-11-08 CN CN201280055221.8A patent/CN104066720A/en active Pending
- 2012-11-08 JP JP2014540456A patent/JP2014532744A/en not_active Withdrawn
- 2012-11-08 AR ARP120104205A patent/AR088799A1/en unknown
- 2012-11-08 MX MX2014005233A patent/MX2014005233A/en not_active Application Discontinuation
- 2012-11-08 WO PCT/EP2012/072143 patent/WO2013068464A1/en not_active Ceased
- 2012-11-08 TW TW101141483A patent/TW201326135A/en unknown
- 2012-11-08 KR KR1020147015421A patent/KR20140091041A/en not_active Withdrawn
- 2012-11-08 EP EP12783220.2A patent/EP2776401A1/en not_active Withdrawn
- 2012-11-08 HK HK15102581.4A patent/HK1202117A1/en unknown
- 2012-11-08 IN IN865KON2014 patent/IN2014KN00865A/en unknown
- 2012-11-08 CA CA2854424A patent/CA2854424A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP2014532744A (en) | 2014-12-08 |
| TW201326135A (en) | 2013-07-01 |
| HK1202117A1 (en) | 2015-09-18 |
| KR20140091041A (en) | 2014-07-18 |
| WO2013068464A1 (en) | 2013-05-16 |
| BR112014011108A2 (en) | 2017-05-16 |
| CN104066720A (en) | 2014-09-24 |
| EP2776401A1 (en) | 2014-09-17 |
| MX2014005233A (en) | 2014-08-22 |
| IN2014KN00865A (en) | 2015-10-02 |
| CA2854424A1 (en) | 2013-05-16 |
| AU2012334068A1 (en) | 2014-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR097325A1 (en) | RINGED PIRROLS | |
| CO2017011174A2 (en) | Ethylene derivatives as metabotropic modulators of glutamate receptors | |
| EA201790599A1 (en) | COMPOUNDS AND COMPOSITIONS AS KINAZ INHIBITORS | |
| EA201690598A1 (en) | AMINOGETEROARIL BENZAMIDES AS KINASE INHIBITORS | |
| EA201591727A1 (en) | BIARYLAMIDE COMPOUNDS AS KINASE INHIBITORS | |
| AR104326A1 (en) | 5-SUBSTITUTED NUCLEOSID COMPOUNDS | |
| PE20170206A1 (en) | SPIROCYCLIC INHIBITORS SUBSTITUTE FOR AUTOTAXIN | |
| EA201490272A1 (en) | NEW 4-PIPERIDINYL COMPOUNDS FOR USE AS TANKIRASE INHIBITORS | |
| AR116115A1 (en) | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | |
| AR100312A1 (en) | DIAMINOTRIAZINE COMPOUNDS | |
| AR100051A1 (en) | DIAMINOTRIAZINE COMPOUNDS | |
| MX378439B (en) | TRIAZINE-BASED RADIOPHARMACEUTICALS AND RADIO-IMAGING AGENTS. | |
| EA201492170A1 (en) | NEW CYPRIDE N-PYRIDINYLAMIDES SUBSTITUTED AS A KINAZ INHIBITOR | |
| MD4626B1 (en) | Tamoxifen derivatives for the treatment of neoplastic disorders, especially high HER2 protein | |
| AR093937A1 (en) | CHEMICAL COMPOUNDS | |
| DOP2011000083A (en) | USEFUL AMIDA COMPOUNDS IN THERAPY | |
| AR089944A1 (en) | DERIVATIVES OF TETRAHIDRO-QUINAZOLINONA | |
| AR094159A1 (en) | COMPOSITE OF [1,2,4] TRIAZOL AND IMIDAZOL REPLACED | |
| AR101196A1 (en) | SUBSTITUTED PYRIMIDINE COMPOUNDS | |
| AR088320A1 (en) | ISOINDOLINONE AND PIRROLOPIRIDINONE DERIVATIVES AS AKT INHIBITORS | |
| AR094527A1 (en) | BIS- [3- (7-TER-BUTIL-2-OXO-3-PHENYL-3H-BENZOFURAN-5-IL) -PROPANOYL POLYGYLENE DERIVATIVES AS ORGANIC MATERIAL STABILIZERS | |
| AR099071A1 (en) | NR2B SELECTIVE ANTAGONISTS | |
| AR090350A1 (en) | CHEMICAL COMPOUNDS | |
| AR088799A1 (en) | CARBOXAMIDE AND UREA DERIVATIVES BASED ON SUBSTITUTED PIRAZOLILS CONTAINING A REPLACED FENILE PORTION WITH A GROUP THAT CONTAINS SO₂ AS VANILLOID RECEIVER LIGANDS | |
| EA201600323A1 (en) | DERIVATIVES OF PIPERAZINE AND THEIR APPLICATION AS A MEDICINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure | ||
| FB | Suspension of granting procedure |